Ixabepilone: all 102 studies that test it

Page 1 of 2. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.TerminatedNCT04796324Phase 2Results posted
• Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)CompletedNCT01446016Phase 2Results posted
• Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With ChemotherapyCompletedNCT01220609Phase 2Results posted
• Ixabepilone in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT01168232Phase 2Results posted
• Ixabepilone + Carboplatin Metastatic Breast CancerCompletedNCT01075100Phase 2Results posted
• Study of Pazopanib and Ixabepilone in Patients With Solid TumorsTerminatedNCT01012362Phase 1Results posted
• Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric CancerCompletedNCT00983801Phase 2Results posted
• Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerActive, not recruitingNCT00977574Phase 2Results posted
• Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast CancerCompletedNCT00924352Phase 1/2Results posted
• Ixabepilone to Treat Cervical CancerTerminatedNCT00924066Phase 2Results posted
• Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney CancerCompletedNCT00923130Phase 2Results posted
• A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial CancerTerminatedNCT00883116Phase 3Results posted
• A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast CancerCompletedNCT00879086Phase 2Results posted
• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast CancerCompletedNCT00866905Phase 2Results posted
• Phase I Combination Ixabepilone + CisplatinCompletedNCT00832117Phase 1Results posted
• Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate CancerCompletedNCT00828308Phase 2Results posted
• Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast CancerCompletedNCT00825734Phase 1/2Results posted
• Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast CancerCompletedNCT00821886Phase 2Results posted
• A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast CancerCompletedNCT00789581Phase 3Results posted
• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast CancerCompletedNCT00785291Phase 3Results posted
• Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast CancerTerminatedNCT00765765Phase 1/2Results posted
• A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung CancerCompletedNCT00723957Phase 2Results posted
• Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung CancerCompletedNCT00683904Phase 1Results posted
• Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerTerminatedNCT00634088Phase 1Results posted
• Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast CancerCompletedNCT00633464Phase 2Results posted
• Phase 1 Trial of Oral IxabepiloneTerminatedNCT00632424Phase 1Results posted
• Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast CancerCompletedNCT00630032Phase 3Results posted
• Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of NeuronsCompletedNCT00627978Phase 2Results posted
• Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast CancerCompletedNCT00593827Phase 2Results posted
• A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast CancerCompletedNCT00568022Phase 1Results posted
• Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast CancerTerminatedNCT00546364Phase 2Results posted
• A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast CancerCompletedNCT00490646Phase 2Results posted
• Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast CancerCompletedNCT00455533Phase 2Results posted
• A Phase I Study of Oral Ixabepilone in Subjects With Advanced CancerCompletedNCT00422097Phase 1Results posted
• A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic CancerCompletedNCT00383149Phase 2Results posted
• A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast CancerCompletedNCT00370552Phase 2Results posted
• Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and ChemotherapyCompletedNCT00331344Phase 1/2Results posted
• Phase I Combination w/ EpirubicinCompletedNCT00322374Phase 1Results posted
• Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced CancerCompletedNCT00207090Phase 1Results posted
• Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian CancerCompletedNCT00182767Phase 1/2Results posted
• Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.CompletedNCT00162136Phase 1Results posted
• Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00095979Phase 2Results posted
• Ixabepilone in Treating Patients With Metastatic Prostate CancerCompletedNCT00087139Phase 2Results posted
• Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedNCT00082433Phase 3Results posted
• Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerCompletedNCT00080301Phase 3Results posted
• Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast CancerTerminatedNCT00079326Phase 2Results posted
• Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast CancerCompletedNCT00077376Phase 2Results posted
• Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaCompletedNCT00058019Phase 2Results posted
• BMS 247550 to Treat Kidney CancerCompletedNCT00030992Phase 2Results posted
• Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous ChemotherapyCompletedNCT00025155Phase 2Results posted
• Ixabepilone and SBRT For Metastatic Breast CancerWithdrawnNCT01818999Phase 2
• A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or CarcinosarcomaStatus unknownNCT01454479Phase 1
• Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT01375829Phase 1
• Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast CancerWithdrawnNCT01349088Phase 1/2
• Ixabepilone and Pemetrexed/Solid TumorsWithdrawnNCT01170871Phase 1
• Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast CancerCompletedNCT01084057Phase 1
• Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After SurgeryWithdrawnNCT01079793Phase 1/2
• Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)TerminatedNCT01057212Phase 2
• A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An AnthracyclineCompletedNCT01027208Phase 2
• Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane ResistantCompletedNCT01019577Phase 2
• Study of Ixabepilone (BMS-247550) in Patients With Solid TumorsCompletedNCT01018966Phase 1
• Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With ChemotherapyWithdrawnNCT00998101Phase 2
• Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid TumorsCompletedNCT00884676Phase 1
• Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic TherapyActive, not recruitingNCT00877500Phase 2
• Lapatinib and Ixabepilone in Treating Patients With Advanced Solid TumorsTerminatedNCT00804310Phase 1
• Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)TerminatedNCT00790894Phase 2
• FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BCCompletedNCT00751868Phase 2
• Solid Tumors Using Ixabepilone and DasatinibCompletedNCT00717704Phase 1
• A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate CancerTerminatedNCT00672009Phase 2
• Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast CancerCompletedNCT00637897Phase 1
• A Study of the Alternative Administration of Ixabepilone and VinflunineCompletedNCT00362830Phase 1
• Ixabepilone in Treating Young Patients With Refractory Solid TumorsCompletedNCT00331643Phase 2
• Ixabepilone Administered as an Enteric Coated Formulation.CompletedNCT00309049Phase 1/2
• Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced MalignanciesCompletedNCT00207129Phase 1
• Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney CancerCompletedNCT00182702Phase 2
• Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid TumorsCompletedNCT00096317Phase 1
• Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)CompletedNCT00080262Phase 2
• Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell TumorsCompletedNCT00070096Phase 2
• Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate CancerCompletedNCT00058084Phase 2
• Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative DisordersCompletedNCT00052572Phase 2
• S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver DysfunctionCompletedNCT00049400Phase 1
• Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00045097Phase 2
• BMS-247550 in Treating Patients With Stage IV MelanomaCompletedNCT00036764Phase 2
• A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based ChemotherapyCompletedNCT00035516Phase 2
• Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and NeckCompletedNCT00033618Phase 2
• Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal CancerCompletedNCT00030706Phase 2
• Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to TherapyCompletedNCT00030108Phase 1
• BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid TumorsTerminatedNCT00028561Phase 1
• Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate CancerCompletedNCT00025194Phase 1/2
• BMS-247550 in Treating Patients With Liver or Gallbladder CancerTerminatedNCT00023946Phase 2
• BMS-247550 in Treating Patients With Advanced Soft Tissue SarcomaTerminatedNCT00022542Phase 2
• BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal CancerCompletedNCT00022477Phase 2
• Ixabepilone in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00021099Phase 2
• BMS-247550 in Treating Women With Metastatic Breast CancerCompletedNCT00020904Phase 2
• BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous TherapyCompletedNCT00020371Phase 1
• BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With ChemotherapyCompletedNCT00017056Phase 2
• BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With ChemotherapyCompletedNCT00017043Phase 2
• BMS-247550 in Treating Patients With Advanced Pancreatic CancerCompletedNCT00016965Phase 2
• BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00016393Phase 2
• BMS-247550 in Treating Patients With Advanced CancersCompletedNCT00006221Phase 1

← Ixabepilone overview